PDS Biotechnology Corporation Overview
Pro stress-test →PDS Biotechnology is a clinical-stage biopharmaceutical company focused on cancer treatment through its proprietary Versamune platform technology, which targets early-stage and late-stage cancers including head and neck, prostate, breast, cervical, and anal cancers. The company recently achieved positive final VERSATILE-002 Phase 2 results and secured FDA alignment for an accelerated approval pathway in January 2026.
Strategic Profile
Pro stress-test →PDS's Versamune platform activates and directs the human immune system to unleash a targeted attack against cancer cells. The platform is designed to activate immune system T-cells to target diseased cells, with key projects including PDS0101 targeting HPV-associated cancers.
Competitive Landscape
Pro stress-test →PDS Biotechnology competes in the cancer immunotherapy space with companies including Arcus Biosciences, Aura Biosciences, BriaCell Therapeutics, Ayala Pharmaceuticals, and Seagen. The company's differentiation lies in its proprietary IL-12-based Versamune platform designed to suppress tumor immunity while generating targeted T cell attacks.
Industry Context
PDS Biotechnology Corporation operates in Biopharmaceutical/Oncology Immunotherapy.
Key facts
Founded: 2005 · Headquarters: Princeton, New Jersey, US · Market cap: $32.2M